Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients-Reference-Cited by-同舟云学术

Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients

Published:2018-03-09 Issue:9 Volume:47 Page:1306-1316
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Chuang W.-L.¹,Jia J.²,Chan H. L. Y.³^ORCID,Han K.-H.⁴,Tanwandee T.⁵,Tan D.⁶,Chen X.²,Gane E.⁷,Piratvisuth T.⁸,Chen L.⁹,Xie Q.⁹,Sung J. J.-Y.³,Messinger D.¹⁰,Wat C.¹¹,Bakalos G.¹²,Liaw Y. F.¹³^ORCID

Affiliation:

1. Kaohsiung Taiwan

2. Beijing China

3. Hong Kong SAR China

4. Seoul Korea

5. Bangkok Thailand

6. Changsha China

7. Grafton New Zealand

8. Hat-Yai Thailand

9. Shanghai China

10. Mannheim Germany

11. Welwyn Garden City UK

12. Basel Switzerland

13. Taipei Taiwan

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14595/fullpdf

Reference19 articles.

1. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013;Schweitzer;Lancet,2015

2. WHO Hepatitis B Fact Sheet (Reviewed July 2017) http://www.who.int/mediacentre/factsheets/fs204/en/

3. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010;Lozano;Lancet,2012

4. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013;Naghavi;Lancet,2015

5. AASLD guidelines for treatment of chronic hepatitis B;Terrault;Hepatology,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of adding on or switching to peginterferon α‐2b in HBeAg‐positive chronic hepatitis B patients with long‐term entecavir treatment: a multicentre randomised controlled trial;Alimentary Pharmacology & Therapeutics;2022-09-20

2. Advances in treatment and prevention of hepatitis B;World Journal of Gastrointestinal Pharmacology and Therapeutics;2021-07-05

3. Advances in treatment and prevention of hepatitis B;World Journal of Gastrointestinal Pharmacology and Therapeutics;2021-07-05

4. HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases;BMC Gastroenterology;2020-04-21

5. Genetic variation inFCER1Apredicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B;Journal of Viral Hepatitis;2019-07-23